New EU Nod For J&J/Genmab's Darzalex Brings It Closer To Rivals
Executive Summary
The EU's CHMP has given the go ahead to extend the EU licence for Janssen/Genmab's Darzalex to include its use earlier in the treatment paradigm, bringing into line with the US label and its rivals.
You may also be interested in...
Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval
The pressure is increasing for Genmab and Janssen to report strong first-line multiple myeloma data for recently launched cancer therapy Darzalex, after development of the drug has been suspended for three hematological indications.
New FDA Revlimid Approval Extends Celgene's Myeloma Empire
Celgene is finally able to market its mainstay multiple myeloma therapy Revlimid for maintenance use after stem cell transplant, after the FDA further expanded its approved indications. The EU is set to follow suit following a CHMP positive opinion last month.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.